WASHINGTON, DC – Peter Alexander, NBC News White House Correspondent, posted an update on October 7 from Regeneron concerning the pharmaceutical company’s REGN-COV2 antibody cocktail for COVID-19 which President Donald Trump received after testing positive for coronavirus.

The statement from Regeneron, posted on Alexander’s Twitter page, read, “Most of the standard assays for IgG would not distinguish btw [between] endogenous (self-made) antibodies and the ones delivered by our therapy. However, given the volume of IgG antibodies delivered in our therapy, and the timing of these tests, it is likely that the second test is detecting REGN-COV2 antibodies.

“Our early data announced last week that the patients most likely to benefit from this treatment have a similar profile to President Trump, in that they had undetectable antibodies at baseline (‘seronegative’) and were early in the course of disease. Treatment with REGN-COV2 had the greatest impact in viral load reduction and time to symptom alleviation in this seronegative group. We also know by looking at the placebo groups that these seronegative patients were at a much higher risk of requiring further medical attention than ‘seropositive’ patients when untreated with therapeutic antibodies.”

As Alexander noted on Twitter, “This is significant because the White House has not said declaratively whether the antibodies found in Trump’s labs are from Regeneron’s antibody cocktail, which Trump took, or antibodies produced by Trump’s own immune system.”

According to Regeneron’s October 2 news release, “Regeneron provided a single 8 gram dose of REGN-COV2, a cocktail of two monoclonal antibodies, for use by President Trump. REGN-COV2 is an investigational COVID-19 therapy, which was provided in response to an Individual Patient Investigational New Drug (IND) application (commonly known as ‘compassionate use’ request) from the President’s physicians.”